MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Munich,,Bavaria,,Germany,-,March,31,2023:,Franklin,Covey,Is

Pre-Market Outlook

BNZI

FIZZ

MINM

MNKD

XPOF

Cinque titoli sono sotto i riflettori a Wall Street. Ecco le aziende che potrebbero influenzare le tendenze della giornata.

Wall Street: 5 azioni da monitorare oggi con i futures in rialzo

Doctor.Healthcare

Long Ideas

News

Markets

Trading Ideas

SSII

Un segnale tecnico le ha messe sotto i riflettori dopo un forte calo. Tre aziende del settore sanitario vicine a una possibile inversione.

3 azioni sanitarie in calo, ma che ora potrebbero decollare

MannKind Corp

Health Care

Press Releases

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Earnings

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

MannKind to Present at Upcoming Investor Conferences

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

MannKind Corporation Reports  Second Quarter 2025 Financial Results And  Provides Business Update

Financing

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Ardelyx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

GRAIL

Janux Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Precigen

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Upstream Bio

Valneva

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

RBC Capital

HC Wainwright & Co.

Mizuho

Wells Fargo

Comments

MannKind

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO